Teva Pharmaceutical Industries Ltd. (TEVA) Friday said it launched an authorized generic of Actoplus Met, or pioglitazone/metformin tablets, in US.
Actoplus met is marketed by Takeda Pharmaceuticals U.S.A Inc. and used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Actoplus met had annual sales of about $413 million in the US, based on IMS sales data as of June 30, 2012.
For comments and feedback: editorial@rttnews.com